Format

Send to

Choose Destination
Br J Anaesth. 2015 Oct;115(4):531-9. doi: 10.1093/bja/aev225. Epub 2015 Jul 18.

European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility.

Author information

1
Malignant Hyperthermia Unit, Leeds Institute of Biomedical and Clinical Sciences, St James's University Hospital, Leeds, UK p.m.hopkins@leeds.ac.uk.
2
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Leipzig, Leipzig, Germany Klinik für Anästhesie, Intensivmedizin, Schmerztherapie, Helios Klinik Schkeuditz, Schkeuditz, Germany.
3
Department of Anaesthesiology, Canisius-Wilhelmina Ziekenhuis, Nijmegen, The Netherlands.
4
Department of Anaesthesia and Research, University of Basel, Basel, Switzerland.
5
Danish Malignant Hyperthermia Centre, Department of Anaesthesia, University Hospital Herlev, Copenhagen, Denmark.
6
Malignant Hyperthermia Unit, Leeds Institute of Biomedical and Clinical Sciences, St James's University Hospital, Leeds, UK.
7
Department of Human Genetics, University of Würzburg, Würzburg, Germany.

Abstract

It is 30 yr since the British Journal of Anaesthesia published the first consensus protocol for the laboratory diagnosis of malignant hyperthermia susceptibility from the European Malignant Hyperthermia Group. This has subsequently been used in more than 10 000 individuals worldwide to inform use of anaesthetic drugs in these patients with increased risk of developing malignant hyperthermia during general anaesthesia, representing an early and successful example of stratified medicine. In 2001, our group also published a guideline for the use of DNA-based screening of malignant hyperthermia susceptibility. We now present an updated and complete guideline for the diagnostic pathway for patients potentially at increased risk of developing malignant hyperthermia. We introduce the new guideline with a narrative commentary that describes its development, the changes to previously published protocols and guidelines, and new sections, including recommendations for patient referral criteria and clinical interpretation of laboratory findings.

KEYWORDS:

CACNA1S; RYR1; excitation–contraction coupling; malignant hyperthermia; malignant hyperthermia susceptibility, diagnosis; skeletal muscle

PMID:
26188342
DOI:
10.1093/bja/aev225
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center